MAPT and early-onset autosomal dominant Alzheimer disease: Consistent with earlier studies demonstrating the efficacy of plasma p-tau217 in detecting Alzheimer’s disease pathology,22,26-28 ROC curve analysis in our study revealed that all three commercially available plasma p-tau217 assays (NULISA, Janssen and ALZpath) exhibited strong performance in identifying abnormal amyloid-PET and tau-PET status.